Data Insights

KN-056 by Alphamab Oncology for Type 2 Diabetes: Likelihood of Approval

KN-056 is under clinical development by Alphamab Oncology and currently in Phase I for Type 2 Diabetes. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - KN-056 in Type 2 Diabetes

Data Insights

Erfonrilimab by Alphamab Oncology for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval

Erfonrilimab is under clinical development by Alphamab Oncology and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Erfonrilimab in Bile Duct Cancer (Cholangiocarcinoma)

Data Insights

Anbenitamab by Alphamab Oncology for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval

Anbenitamab is under clinical development by Alphamab Oncology and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Anbenitamab in Gastroesophageal (GE) Junction Carcinomas

Data Insights

Anbenitamab by Alphamab Oncology for Gastric Cancer: Likelihood of Approval

Anbenitamab is under clinical development by Alphamab Oncology and currently in Phase I for Gastric Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Anbenitamab in Gastric Cancer

Data Insights

JSKN-003 by Alphamab Oncology for Esophageal Cancer: Likelihood of Approval

JSKN-003 is under clinical development by Alphamab Oncology and currently in Phase I for Esophageal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - JSKN-003 in Esophageal Cancer

Data Insights

JSKN-003 by Alphamab Oncology for Gastric Cancer: Likelihood of Approval

JSKN-003 is under clinical development by Alphamab Oncology and currently in Phase I for Gastric Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - JSKN-003 in Gastric Cancer

Data Insights

JSKN-003 by Alphamab Oncology for Head And Neck Cancer: Likelihood of Approval

JSKN-003 is under clinical development by Alphamab Oncology and currently in Phase I for Head And Neck Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - JSKN-003 in Head And Neck Cancer

Data Insights

JSKN-003 by Alphamab Oncology for Lung Cancer: Likelihood of Approval

JSKN-003 is under clinical development by Alphamab Oncology and currently in Phase I for Lung Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - JSKN-003 in Lung Cancer

Data Insights

JSKN-003 by Alphamab Oncology for Breast Cancer: Likelihood of Approval

JSKN-003 is under clinical development by Alphamab Oncology and currently in Phase I for Breast Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - JSKN-003 in Breast Cancer

Data Insights

Erfonrilimab by Alphamab Oncology for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval

Erfonrilimab is under clinical development by Alphamab Oncology and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Erfonrilimab in Metastatic Hepatocellular Carcinoma (HCC)

Data Insights

Erfonrilimab by Alphamab Oncology for Thymic Carcinoma: Likelihood of Approval

Erfonrilimab is under clinical development by Alphamab Oncology and currently in Phase II for Thymic Carcinoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Erfonrilimab in Thymic Carcinoma

Data Insights

Erfonrilimab by Alphamab Oncology for Colorectal Cancer: Likelihood of Approval

Erfonrilimab is under clinical development by Alphamab Oncology and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Erfonrilimab in Colorectal Cancer

Data Insights

JSKN-003 by Alphamab Oncology for Bladder Cancer: Likelihood of Approval

JSKN-003 is under clinical development by Alphamab Oncology and currently in Phase I for Bladder Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - JSKN-003 in Bladder Cancer

Data Insights

Envafolimab by Alphamab Oncology for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval

Envafolimab is under clinical development by Alphamab Oncology and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Envafolimab in Pancreatic Ductal Adenocarcinoma

Data Insights

Envafolimab by Alphamab Oncology for Cutaneous Squamous Cell Carcinoma (cSCC): Likelihood of Approval

Envafolimab is under clinical development by Alphamab Oncology and currently in Phase II for Cutaneous Squamous Cell Carcinoma (cSCC). According...

Likelihood of Approval and Phase Transition Success Rate Model - Envafolimab in Cutaneous Squamous Cell Carcinoma (cSCC)

Data Insights

Envafolimab by Alphamab Oncology for Head And Neck Cancer: Likelihood of Approval

Envafolimab is under clinical development by Alphamab Oncology and currently in Phase I for Head And Neck Cancer. According to...

Data Insights

Envafolimab by Alphamab Oncology for Metastatic Prostate Cancer: Likelihood of Approval

Envafolimab is under clinical development by Alphamab Oncology and currently in Phase I for Metastatic Prostate Cancer. According to GlobalData,...

Data Insights

Envafolimab by Alphamab Oncology for Bladder Cancer: Likelihood of Approval

Envafolimab is under clinical development by Alphamab Oncology and currently in Phase I for Bladder Cancer. According to GlobalData, Phase...

Data Insights

Erfonrilimab by Alphamab Oncology for Pancreatic Cancer: Likelihood of Approval

Erfonrilimab is under clinical development by Alphamab Oncology and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase...

Data Insights

Envafolimab by Alphamab Oncology for Gastrointestinal Tract Cancer: Likelihood of Approval

Envafolimab is under clinical development by Alphamab Oncology and currently in Phase I for Gastrointestinal Tract Cancer. According to GlobalData,...